How to manage relapsed/refractory MCL - new agents and unmet needs
Benefits of deacetylase inhibitors for leukemia therapy
Alisertib for the treatment of peripheral T-cell lymphoma
Do immunoglobulin receptor interactions play a role in CLL?
iwCLL 2017 program: the biology of CLL, treatment options and the relapsed/refractory setting